EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Epigenetic regulation of EZH2 by ncRNAs: mechanisms and oncogenic implications

Hussein Salim Abed, N Esanmurodova, Abhinav Kumar, Soumya V Menon, Mandeep Kaur, Mahamedha Deorari, Baneen Chasib Gabal, Yasser Fakri Mustafa, Irshad Ahmad

Naunyn-Schmiedeberg's Archives of Pharmacology · 2026

DOI: 10.1007/s00210-025-04528-7 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2026. Verfasst von Hussein Salim Abed und 8 weiteren Autor:innen. Beteiligte Einrichtung: Medical Laboratory Techniques Department, College of Health and Medical Technology, University of Al-maarif, Anbar, Iraq. Hussein.salem@uoa.edu.iq. Hauptthemen laut MEDLINE: Enhancer of Zeste Homolog 2 Protein, Epigenesis, Genetic, Neoplasms, RNA, Untranslated. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 162 Literaturangaben. Gefördert von: Deanship of Scientific Research, King Khalid University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Enhancer of zeste homolog 2 (EZH2), a histone methyltransferase and core component of the polycomb repressive complex 2 (PRC2), is an important player in cancer progression through its powerful effects on chromatin remodeling and gene silencing. In addition to its classical role in regulating the cell cycle and tumor proliferation, numerous publications have identified the broad role of EZH2 in modulating the tumor immune microenvironment (TIME), leading to immune evasion and resistance to immunotherapy. EZH2 has been shown to silence immune surveillance genes by binding to H3K27me3 histone, leading to epigenetic silencing in lymphomas and thereby reducing tumor immunogenicity, which facilitates immune escape. EZH2 also modulates the recruitment and activity of immunosuppressive cells by epigenetically modifying cytokine and chemokine networks. Importantly, EZH2 upregulates PD-L1 expression either directly or indirectly through its pro-oncogenic activation of STAT3 signaling, which induces T cell exhaustion and ultimately resistance to checkpoint inhibitors in cancers such as breast cancer and glioblastoma. Furthermore, EZH2 also influences the regulation of immune-related microRNAs, including the suppression of the miR-144/451a cluster, which encourages immunosuppressive macrophage polarization. Pharmacological EZH2 inhibition has been shown to be an arm of a synergistic therapy, combining immune checkpoint blockade therapies, which can reinstate antigen presentation and T cell infiltration, highlighting EZH2 as an essential epigenetic modulator of tumor-immune interactions. It remains a viable target for therapy to overcome immune resistance and improve cancer immunotherapy outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Enhancer of Zeste Homolog 2 ProteinEpigenesis, GeneticNeoplasmsRNA, UntranslatedHumansAnimalsTumor MicroenvironmentMicroRNAsGene Expression Regulation, Neoplastic

Stichwörter der Autor:innen

CancerEZH2LncRNAMiRNAPathogenesis

Substanzen

Enhancer of Zeste Homolog 2 ProteinEZH2 protein, humanRNA, UntranslatedMicroRNAs

Autor:innen und Institutionen

  • Medical Laboratory Techniques Department, College of Health and Medical Technology, University of Al-maarif, Anbar, Iraq. Hussein.salem@uoa.edu.iq.
  • Department of Physics and Chemistry, Tashkent Institute of Irrigation and Agricultural Mechanization Engineers, National Research University, Tashkent, Uzbekistan. N.esanmurodova@hotmail.com.
  • Western Caspian University, Scientific Researcher, Baku, Azerbaijan. N.esanmurodova@hotmail.com.
  • Centre for Research Impact & Outcome, Chitkara University Institute of Engineering and Technology, Chitkara University, Rajpura, 140401, Punjab, India.
  • Department of Chemistry and Biochemistry, School of Sciences, JAIN (Deemed to Be University), Bangalore, Karnataka, India.
  • Department of Sciences, Vivekananda Global University, Jaipur, Rajasthan, 303012, India.

Förderung

  • Deanship of Scientific Research, King Khalid University

Zitieren

APA

Abed, H. S., Esanmurodova, N., Kumar, A., Menon, S. V., Kaur, M., Deorari, M., Gabal, B. C., Mustafa, Y. F., & Ahmad, I. (2026). Epigenetic regulation of EZH2 by ncRNAs: mechanisms and oncogenic implications. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-025-04528-7

Vancouver

Abed HS, Esanmurodova N, Kumar A, Menon SV, Kaur M, Deorari M, et al. Epigenetic regulation of EZH2 by ncRNAs: mechanisms and oncogenic implications. Naunyn-Schmiedeberg's Archives of Pharmacology. 2026. doi:10.1007/s00210-025-04528-7

BibTeX
@article{Abed2026,
  author = {Abed, Hussein Salim and Esanmurodova, N and Kumar, Abhinav and Menon, Soumya V and Kaur, Mandeep and Deorari, Mahamedha and Gabal, Baneen Chasib and Mustafa, Yasser Fakri and Ahmad, Irshad},
  title = {Epigenetic regulation of EZH2 by ncRNAs: mechanisms and oncogenic implications},
  journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
  year = {2026},
  doi = {10.1007/s00210-025-04528-7}
}
Kostenlos starten →